Unternehmen Novartis CBOE EUROPE EQUITIES
Aktien
0QLR
CH0012005267
0QLR
Pharmazeutika
Schlusskurs
Andere Börsenplätze
|
||
- EUR | - |
|
25.06. | Aktien Schweiz nach deutlichem Vortagesplus mit Abgaben | DJ |
24.06. | Aktien Schweiz Schluss: SMI über 12'100 Punkten - Schwergewichte ziehen | AW |
Kurzporträt
- Onkologie (29,9%);
- Immunologie (17,2%);
- Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (14,1%);
- Neurologie (8,9%).
Der restliche Umsatz (29,9%) wird aus der Auftragsfertigung von Pharmaprodukte erzielt.
Ende 2023 verfügte die Novartis AG über 33 Produktionsstandorte auf der ganzen Welt.
Die geographische Umsatzverteilung sieht aus wie folgt: Europa (33%), USA (39,5%), Asien / Afrika / Australasien (20,5%), Kanada und Lateinamerika (7%).
Umsatz nach Geschäftsbereich
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Umsatz je Region
CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4,28 % |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26,41 % |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25,63 % |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25,94 % |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1,73 % |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23,04 % |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17,90 % |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27,09 % |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26,88 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 48 | 01.01.05 | |
Director of Finance/CFO | 59 | 01.01.03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16.05.22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01.04.17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01.12.18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01.01.04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01.08.13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01.05.22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01.09.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01.01.13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28.02.20 |
Chairman | 68 | 01.01.13 | |
John Young
BRD | Director/Board Member | 60 | 07.03.23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 28.02.20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01.01.16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01.01.13 |
Nancy Andrews
BRD | Director/Board Member | 65 | 01.01.15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28.02.19 |
Frans van Houten
BRD | Director/Board Member | 64 | 28.02.17 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 2 189 930 497 | 1 866 336 959 ( 85,22 %) | 233 443 766 ( 10,66 %) | 85,22 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
NOVARTIS AG 6,63% | 145 083 991 | 6,63% | 14 983 623 163 $ |
MORPHOSYS AG 51,00% | 19 235 376 | 51,00% | 1 433 544 095 $ |
SANDOZ GROUP AG 2,99% | 12 886 900 | 2,99% | 457 966 018 $ |
NOVARTIS INDIA LIMITED 70,68% | 17 450 680 | 70,68% | 218 239 949 $ |
THIRD HARMONIC BIO, INC. 6,45% | 2 642 762 | 6,45% | 35 175 162 $ |
ERASCA, INC. 4,74% | 12 307 692 | 4,74% | 31 015 384 $ |
OCULIS HOLDING AG 4,66% | 1 713 521 | 4,66% | 20 151 007 $ |
MOLECULAR PARTNERS AG 4,74% | 1 739 130 | 4,74% | 6 554 381 $ |
413 581 | 5,97% | 5 335 195 $ |
Unternehmenskontakt
![Straße Novartis(0QLR)](https://cdn.zonebourse.com/static/address/16414098.png)
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Novartis Healthcare Pvt Ltd.
![]() Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Investment Ltd.
| |
Novartis Holding AG
![]() Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. |
Financial Conglomerates
|
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
| |
Novartis Finance SA
|
Finance/Rental/Leasing
|
Novartis BioVenturesAG
![]() Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland. |
Investment Managers
|
Novartis Investments SARL
![]() Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg. |
Financial Conglomerates
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+54,88 % | 815 Mrd. | |
+45,62 % | 654 Mrd. | |
-6,76 % | 354 Mrd. | |
+21,96 % | 337 Mrd. | |
+10,49 % | 302 Mrd. | |
+17,85 % | 247 Mrd. | |
+2,13 % | 229 Mrd. | |
+9,86 % | 171 Mrd. | |
-3,31 % | 159 Mrd. |
- Börse
- Aktien
- 904278 Aktie
- 0QLR Aktie
- Unternehmen Novartis